平台简介

——

创新型Ii-Key多肽技术具有30余年研发历史，以靶向T细胞免疫为主，克服了多肽体内易降解、免疫原性弱等行业难题，使得该多肽技术成为制药和疫苗产业的可靠的技术平台。同时Ii-Key技术也改变了过往T细胞免疫激活机制，开创了体内靶向T细胞免疫技术。

基于该平台已经注册专利10余项，在传染病和肿瘤领域布局产品管线20余条，其中AE37疫苗已在美国完成IIb期临床三阴性乳腺癌联合用药试验，GP2完成HER2阳性乳腺癌II期临床试验，前列腺癌、膀胱癌疫苗完成IIa期临床试验，猪流感、禽流感和黑色素瘤疫苗在美国已完成I期临床试验；RSV、HPV、HIV疫苗已开展临床前研究，研究数据显示产品具备很高的临床研究价值；新冠疫苗已获尼日利亚临床试验批准和巴西临床伦理批准。综上临床实验数据显示，Ii-Key多肽疫苗安全性非常高，无一例2级以上副作用发生。

国家立项

• 2021年3月和11月，中国疾病预防控制中心病毒病预防控制所将Ii-Key多肽新冠疫苗作为国家“二代通用型新冠疫苗”上报国务院联防联控机制
• 2022年7月，国家十四五重点研发计划“战略性科技创新合作”重点专项2022年度科技抗疫国际合作定向项目获批
• 2022年12月，国家十四五重点研发计划病原学与防疫技术体系研究专项“新型冠状病毒预防性鼻喷Ii-Key多肽疫苗的研究”青年科学家项目获批

部分专利

——

• Ii-Key/antigenic peptide vaccines
• II-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
• HUMAN PAPILLOMAVIRUS / II-KEY HYBRIDS AND METHODS OF USE
• II-KEY ENHANCED VACCINE POTENCY
• II-KEY/HER-2/NEU HYBRID CANCER VACCINE
• II-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
• T CELL EPITOPE CLUSTERS AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19
• 一种多佐剂制备多组分疫苗的方法
• Ii-Key杂合体及其在制备肿瘤疫苗中的应用
• Ii-Key/HPV16 E7/MHC杂交肽及应用
• 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用
• 新型冠状病毒奥密克戎系列变异株Ii-Key T细胞多肽及其应用

部分文献

——

• Prospective, randomized, single blinded, multi center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Received: 27 October 2019 / Accepted: 8 April 2020
• Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol. 1995 Jun;25(6):1693-702.
• Adams S, Albericio F, Alsina J, Smith ER, Humphreys RE. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittelforschung. 1997 Sep;47(9):1069-77.
• Xu M, Jackson R, Adams S, Humphreys RE. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung. 1999 Sep;49(9):791-9.
• Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine. 2000; 18:2693-7.
• Xu M, Qiu G, Jiang Z, von Hofe E, Humphreys RE. Genetic modulation of tumor antigen presentation. Trends Biotechnol. 2000;18:167-72. Review.
• Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001; 54:39-44.
• Drabner B, Reineke U, Schneider-Mergener J, Humphreys RE, Hartmann S, Lucius R. Identification of T helper cell-recognized epitopes in the chitinase of the filarial nematode Onchocerca volvulus. Vaccine. 2002; 20:3685-94.
• Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther 2003; 10:1512-8.
• Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Human Gene Therapy 2003; 14: 763-75.
• Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 2003; 52:592-8.
• Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 2003; 21:4128-32.
• Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, and Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing established tumors. Cancer Treatment Reviews 2004; 30:281-90.
• Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother. 2004; 53:490-6.
• Xu M, Lu X, Kallinteris NL, Wang Y, Wu S, von Hofe E, Gulfo J, Humphreys RE, Hillman GG. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr Opin Mol Ther. 2004; 6:160-5.
• Humphreys RE, Hillman GG, von Hofe E, Xu M. Forcing Tumor Cells to Present Their Own Tumor Antigens to the Immune System: A Necessary Design for an Efficient Tumor Immunotherapy. J Cellular and Mol Imm 2004; 1:180-185
• Wang Y, Xu M, Che M, Hofe EV, Abbas A, Kallinteris NL, Lu X, Liss ZJ, Forman JD, Hillman GG. Curative Antitumor Immune Response Is Optimal with Tumor Irradiation Followed by Genetic Induction of Major Histocompatibility Complex Class I and Class II Molecules and Suppression of Ii Protein. Hum Gene Ther. 2005;16:187-99.
• Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine. 2005;18:2336-8.
• Kallinteris NL, Wu S, Lu X, Humphreys RE, von Hofe E, Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother. 2005 Jul-Aug;28(4):352-8.
• Kallinteris NL, Powell D, Blackwell CE, Kim M, Lu X, Wu S, Humphreys RE, Xu M, von Hofe E. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci. 2006 Jan 1;11:46-58.
• Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther. 2006 Dec;6(12):1311-21. Review.
• Lu X, Wu S, Blackwell CE, Humphreys RE, von Hofe E, Xu M. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine. Immunology. 2007 Feb; 120(2):207-16.
• Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN. Ii-Key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother. 2007 May;56(5):601-13.
• Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer. 2007 Nov 1;121(9):2031-41.
• Wambre E, Van Overtvelt L, Maillère B, Humphreys R, von Hofe E, Ferhat L, Ebo D, Moingeon P. Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspects. Int Arch Allergy Immunol. 2008 Jan;146(2):99-112.
• Chou CL, Mirshahidi S, Su KW, Kim A, Narayan K, Khoruzhenko S, Xu M, Sadegh-Nasseri S. Short peptide sequences mimic HLA-DM functions. Mol Immunol. 2008 Apr;45(7):1935-43.
• Van Overtvelt L, Wambre E, Maillère B, von Hofe E, Louise A, Balazuc AM, Bohle B, Ebo D, Leboulaire C, Garcia G, Moingeon P. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol. 2008 Apr 1;180(7):4514-22.
• Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008 Jul 10;26(20):3426-33.
• Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther. 2009 Jan;9(1):71-8. Review.
• Xu M, Lu X, Sposato M, Zinckgraf JW, Wu S, von Hofe E. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. Vaccine. 2009 Jul 23;27(34):4641-7.
• Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. Vaccine. 2009 Aug 27;27(39):5393-401.
• Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. A new era in anticancer peptide vaccines. Cancer. 2010 May 1;116(9):2071-80.
• Perez SA, Kallinteris NL, Stratos B, Tzonis PK, Georgakopoulou K, Thanos A, Varla-Leftherioti M, Papamichail M, von Hofe E, Baxevanis CN. Results From a Phase 1 Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer. Clin Cancer Res. 2010 Jul 1;16(13):3495-506. Epub 2010 May 13
• Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010 Nov 3;28(47):7476-82. -82. Epub 2010 Sep 19
• Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines. 2011 Feb;10(2):201-10.
• Vadacca M, Valorani MG, von Hofe E, Kallinteris NL, Buzzetti R, Pozzilli P. Recognition of Ii-Key/HC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes. Horm Metab Res. 2011 Jun;43(7):483-8. Epub 2011 Apr 21
• Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells. J Immunol. 2011 Jul 1;187(1):316-24. Epub 2011 May 25.
• Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011 Sep 6. [Epub ahead of print]
• von Hofe E. A new ally against cancer. Scientific American 2011 Oct;305(4):66-71.
• Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence